Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade Research Letter


Authors: Asdourian, M. S.; Shah, N.; Jacoby, T. V.; Semenov, Y. R.; Otto, T.; Thompson, L. L.; Dee, E. C.; Reynolds, K. L.; Chen, S. T.
Title: Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade
Keywords: aged; major clinical study; overall survival; cancer patient; neoplasm; neoplasms; progression free survival; combination chemotherapy; medical record review; psoriasis; monoclonal antibody; pruritus; rash; skin; maculopapular rash; antibodies, monoclonal; immunotherapy; cytotoxic t lymphocyte antigen 4; massachusetts; measles like rash; administration, cutaneous; programmed death 1 receptor; adverse event; vitiligo; hypersensitivity; immune checkpoint inhibitor; eczema; lichenoid; humans; human; male; female; article; immune checkpoint inhibitors; icd-10; cutaneous drug administration
Journal Title: Journal of the American Academy of Dermatology
Volume: 88
Issue: 2
ISSN: 0190-9622
Publisher: Mosby Elsevier  
Date Published: 2023-02-01
Start Page: 485
End Page: 487
Language: English
DOI: 10.1016/j.jaad.2022.06.030
PUBMED: 35738514
PROVIDER: scopus
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Edward Christopher Dee
    253 Dee